TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04439760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Cervical Ganglion Block
Description: Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
Study: NCT04386213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary artery in-stent restenosis
Description: treat the petients with coronary artery in-stent restenosis
Study: NCT01883765

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive Training
Study: NCT03131141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC-3781
Description: Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
Study: NCT04386213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery in-stent restenosis
Description: treat the petients with coronary artery in-stent restenosis
Study: NCT02244554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
Study: NCT02825043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula
Description: This is a humidified oxygen delivery system.
Study: NCT03582137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to this arm will receive Placebo
Study: NCT00377598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
Study: NCT00774111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 50 mg in combination with Etravirine
Study: NCT00990756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03526299
Description: dry powder for inhalation, 1.396 mg, BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03526299
Description: dry powder for inhalation, 4 mg, BID for 14 days
Study: NCT04551157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Viewing
Description: Two patient information videos containing practical advice from staff about the recovery process, images of the wound throughout the healing process and ways to cope with the range of emotional responses that patients report following an open fracture.
Study: NCT00955461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RevLite laser treatment
Description: Electro-optic Q-Switched Nd: YAG Laser treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser treatment
Study: NCT00250224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy stent
Study: NCT00578227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix ™ Paediatric
Description: Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix ™ Paediatric
Description: Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
Study: NCT04795102

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: immediate implant placement with ATBG and L-PRF
Description: immediate implant placement using ATBG as a graft material, with L-PRF

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with ATBG
Description: immediate implant placement using ATBG as a graft material without L-PRF
Study: NCT04569279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
Study: NCT00916006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Gel
Description: 0.015%, three day treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle gel, three day treatment
Study: NCT03008941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Capsules with fecal microbiota from healthy donors

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT02189603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant (E. Coli) Hepatitis E Vaccine
Study: NCT02763553

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Feed
Description: A low-carbohydrate, high-fat feed designed to induce a ketotic state.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Feed
Description: Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
Study: NCT02871765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education related Warfarin
Description: Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
Study: NCT04161222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Experimental group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Control group will perform a typical warm-up of competitive football
Study: NCT02117115

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computed tomography
Description: CT scan performed between Day +7 and Day +14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioversol
Description: To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
Study: NCT01664234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laryngoscopy with oxygen
Description: Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laryngoscopy without oxygen
Description: Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
Study: NCT02189603

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant (E. Coli) Hepatitis E Vaccine
Study: NCT03840070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenfill
Description: Maximum: 22ml
Study: NCT06239662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Group
Description: The first part of each meeting, lasting 45 minutes, will be held only with children and young people, while parents will wait in the waiting room. At the end of the first part, for each meeting, the children will be asked to make a commitment relating to the topics covered, which will be verified in the following meeting. Once the part with the patients has concluded, they will be accompanied to an adjacent environment where a pediatrician volunteer will be waiting for them and will offer fun and socialization activities. In the meantime, the parents will be seated and will address, together with the team staff, the same issues discussed with their children, again for a duration of approximately 45 minutes. Parents will also be invited to make a commitment similar to that required of children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The dietician will meet individually each child together with parents. Dietician will provide nutritional advices.
Study: NCT01675830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Retention Head Wrap
Description: Applied to infant's heads during the rewarming phase of CBP surgery
Study: NCT00690469

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02196012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention control condition
Study: NCT04410705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave theraphy for hamstring tendinopathy
Description: For hamstring tendinopathy; a total of 2000 impulses will be done. We will apply twice a week and 5 times in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave theraphy for quadriceps tendinopathy
Description: Energy flux density will be 0.58mJ/mm2 (2 bar) with 2000 impulses. We will perform twice a week, 5 times in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave theraphy for achilles tendinopathy
Description: Each session consisted of 2400 impulses will be administered with an energy flux density ranged from 0.17 to 0.25 mJ/mm2 (1.7-2.5 bar). We will perform once a week, 3 times in total.
Study: NCT03677947

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and response prevention
Description: ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inference-based cognitive therapy
Description: The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
Study: NCT02069847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide.
Study: NCT02386072

Intervention type: DRUG
Intervention: mirabegron
Description: oral
Study: NCT00899535

Intervention type: GENETIC
Intervention: DNA analysis

Intervention type: GENETIC
Intervention: RNA analysis

Intervention type: GENETIC
Intervention: microarray analysis

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: polymorphism analysis
Study: NCT04631133

Intervention type: DEVICE
Intervention: Lumbar Implant for Stiffness Augmentation (LISA)
Description: The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
Study: NCT01573819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
Study: NCT02634281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Study: NCT01773772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls \< 42kg and 50 mg given to those or = to 42 kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
Study: NCT01715714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin Recapture Therapy
Description: Given 12h and 2h before CABG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given 12h and 2h before CABG.
Study: NCT02793466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab; MEDI4736
Description: IV Infusion every 2 weeks for a maximum of 26
Study: NCT00590798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Patient will walk within 30 minutes of vascular closure system procedure
Study: NCT02484287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Integra External Drainage Catheter.
Description: Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Ventriclear EVD Antibiotic Catheter
Description: Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Codman Bactiseal EVD Catheter Set
Description: Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
Study: NCT02386072

Intervention type: DRUG
Intervention: antimuscarinic medication
Description: oral
Study: NCT05360225

Intervention type: DIAGNOSTIC_TEST
Intervention: therascreen® KRAS RGQ PCR Kit
Description: The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
Study: NCT02232932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAPECITABINE-Radiotherapy -Liver Transplantation
Description: CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RESECTION
Description: Intent-to-treat R0 liver resection
Study: NCT02979717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein, high fiber dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low protein, low fiber comparator
Study: NCT01234207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard, non-free-form, non-customized PAL spectacles
Description: Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard, non-free-form, non-customized PAL spectacles
Description: Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Individually customized free-form surfaced PAL spectacles
Description: Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Individually customized free-form surfaced PAL spectacles
Description: Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt